Olema Pharmaceuticals, Inc.
OLMA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $124,517 | $86,140 | $82,274 | $51,100 |
| G&A Expenses | $17,741 | $18,821 | $24,714 | $20,391 |
| SG&A Expenses | $17,741 | $18,821 | $24,714 | $20,391 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $142,258 | $104,961 | $106,988 | $71,491 |
| Operating Income | -$142,258 | -$104,961 | -$106,988 | -$71,491 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $12,784 | $8,306 | $2,201 | $395 |
| Pre-Tax Income | -$129,474 | -$96,655 | -$104,787 | -$71,096 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$129,474 | -$96,655 | -$104,787 | -$71,096 |
| % Margin | – | – | – | – |
| EPS | -2.2 | -2.14 | -2.62 | -1.79 |
| % Growth | -2.8% | 18.3% | -46.4% | – |
| EPS Diluted | -2.2 | -2.14 | -2.62 | -1.79 |
| Weighted Avg Shares Out | 58,744 | 45,247 | 39,995 | 39,524 |
| Weighted Avg Shares Out Dil | 58,744 | 45,247 | 39,995 | 39,524 |
| Supplemental Information | – | – | – | – |
| Interest Income | $12,682 | $8,325 | $2,228 | $442 |
| Interest Expense | $0 | – | $0 | – |
| Depreciation & Amortization | $393 | $377 | $357 | $163 |
| EBITDA | -$141,865 | -$104,584 | -$106,631 | -$71,328 |
| % Margin | – | – | – | – |